Adaptive Phage Therapeutics

About:

Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria.

Website: http://www.aphage.com

Twitter/X: AdaptivePhageTx

Top Investors: Alexandria Venture Investments, Deerfield, Mayo Clinic, U.S. Department of Defense, AMR Action Fund

Description:

Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria. Its services are provided using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistant bacteria.

Total Funding Amount:

$132M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Bethesda, Maryland, United States

Founded Date:

2016-01-01

Founders:

Carl Merril, Greg Merril

Number of Employees:

51-100

Last Funding Date:

2023-06-13

IPO Status:

Private

Industries:

© 2025 bioDAO.ai